|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We demonstrate that target antigen modulation is a promising strategy to improve CD22 CAR efficacy and remission durability in patients with leukemia and lymphoma.<i>See related commentary by Guedan and Delgado, p. 5188</i>.
|
31110075 |
2019 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several other cell surface tumor antigens, such as CD20 and CD22, found in the majority of leukemias and lymphomas are considered potential targets by pharmaceutical companies and research organizations, and trials have been ongoing in this direction.
|
31578576 |
2019 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD22-directed CAR-T cells have shown efficacy against leukemia as well in a recent clinical trial, representing the first alternative CAR target to approach comparable efficacy to CD19 CAR-T cells.
|
30120708 |
2018 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The anti-leukemic activity of this RTM against BPL xenograft clones derived from CD22ΔE12(+) leukemia patients provides the preclinical proof-of-concept that correcting the CD22ΔE12 defect with rationally designed CD22 RTMs may provide the foundation for therapeutic innovations that are needed for successful treatment of high-risk and relapsed BPL patients.
|
25567759 |
2015 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Since latest generation immunotoxins are composed of a toxic domain genetically fused to antibody fragment(s) which confer on the IT target selective specificity, we rescued from the hydridoma 4KB128, a recombinant single-chain variable fragment (scFv) targeting CD22, a marker antigen expressed by B-lineage leukaemias and lymphomas.
|
25889802 |
2015 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We have successfully complexed our rationally designed lead CD22-RTM with PVBLG-8 to prepare a non-viral nanoscale formulation of CD22ΔE12-RTM with potent anti-cancer activity against CD22ΔE12(+) B-lineage leukemia and lymphoma cells.
|
26288837 |
2015 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since CD22 is ubiquitously expressed in the B-cell lineage and CD22 endocytosis can be triggered efficiently, antibodies and antibody-based immunotoxins against CD22 are used to target B cells both in B-cell lymphomas and leukemias, as well as in autoimmune diseases.
|
22777817 |
2012 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expression of this structurally and functionally abnormal CD22 protein is associated with a very aggressive in vivo growth of patients' primary leukemia cells causing disseminated overt leukemia in SCID mice.
|
20841423 |
2010 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias.
|
20628151 |
2010 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data support the testing of RFB4(dsFv)-PE38 in patients with CD22+ leukemias and lymphomas, which is presently under way.
|
10778980 |
2000 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2.
|
8643111 |
1995 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Patients with CD34+ leukemia were more likely to have blasts expressing CD22, CD9, and CD13 antigens but were less likely to coexpress CD20.
|
1696310 |
1990 |